Insomnia

Redefining Insomnia: State-of-the-Science in Insomnia Management

INSTRUCTIONS

Click on the link to enter the activity below. After listening to both audio cases in their entirety, follow the link to take the posttest and evaluation.

After completing both audio cases and the posttest and evaluation, a continuing education certificate will automatically be generated and should be printed or saved to your computer for your records.

Thank you for your participation.

Redefining Insomnia: State-of-the-Science Insomnia Management – Audio Case Studies

Term of Approval

Release Date : January 2008

Expiration Date : January 31, 2009

Program Overview

As many as one-third of adults in the United States suffer from insomnia, which has been linked to increased work absence, decreased job performance, and decreased life expectancy. Nearly 10% of insomnia sufferers describe their insomnia as serious or chronic. Insomnia is also implicated in motor function and cognitive impairment, increased body mass index, and increased insulin resistance. Despite those grave consequences and a high prevalence, insomnia is often not perceived as a condition serious enough to warrant a physician visit. The perception that insomnia is somehow benign results in low treatment rates among patients who suffer from this sleep disorder either by itself or as a comorbid condition. The National Institutes of Health (NIH) State of the Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults provides guidelines for the diagnosis and treatment of acute and chronic insomnia. These case studies offer recommendations for appropriate management of 2 patients with this disorder.

Intended Audience

This activity was developed for primary care physicians, psychiatrists, pharmacists, and other healthcare professionals involved in the management of patients with chronic insomnia.

Method of Participation and Obtaining CME Credit

CME credit is offered upon successful completion of the posttest. Certificates will be issued to participants after completion and receipt of the CME Demographic and Evaluation Form and successful completion of the posttest with a passing score of 70% or higher.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

•  Understand the NIH State-of-the-Science Conference Statement recommendations on current practice

•  Define normal sleep and insomnia

•  Identify comorbidities and risk factors for chronic insomnia

•  Recognize the consequences of chronic insomnia

•  Describe approaches to diagnosis and assessment

•  Analyze non-pharmacologic and pharmacologic interventions for managing chronic insomnia

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Summit Institute of Knowledge, Inc., and International Medical Press (IMP). Summit Institute of Knowledge, Inc., is accredited by the ACCME to provide continuing medical education for physicians.

ACPE Logo Summit Institute of Knowledge, Inc., is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Credit Designation Statements

Summit Institute of Knowledge, Inc., designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity will provide 1.5 hours (0.15 CEUs) of credit. The ACPE Universal Program Number is 442-999-07-002-H01P.

Disclosures

In compliance with the ACCME and the ACPE, it is the policy of Summit Institute of Knowledge, Inc., and IMP to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals involved in planning (eg, CME provider staff, faculty, and planners) are expected to disclose any significant financial relationships with commercial interests over the past 12 months . Summit also requires that faculty identify and reference off-label product or investigational uses of pharmaceutical and medical device products.

All conflicts of interest have been mitigated and resolved through the use of a peer review process.

FACULTY

Dipak V. Vashi , MD

Speakers Bureau: Boehringer Ingelheim; Novartis; sanofi-aventis

Dr Vashi has disclosed that he anticipates discussing unlabeled uses of the following products in this educational activity: trazodone, nortriptyline, amitriptyline, doxepin, mirtazapine.

Dr Vashi has disclosed that he anticipates discussing the following investigational products in this educational activity: gaboxadol, indiplon, eplivanserin.

CME PROVIDER AND EDUCATIONAL PARTNER STAFF

All staff of Summit Institute of Knowledge, Inc., and IMP in a position to influence content have filed statements of disclosure with the CME provider. Any conflicts of interest were identified and resolved prior to their involvement in planning this activity. These disclosures are available for review by contacting Amy Groves at 1 404 443 1596 or e-mail at amy.groves@intmedpress.com.

Summit Institute of Knowledge, Inc., and IMP staffs have disclosed no conflicts of interest.

Disclaimer

This activity is designed for healthcare professionals for educational purposes. Information and opinions offered by the faculty represent their own viewpoints. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information.

While Summit Institute of Knowledge, Inc., makes every effort to have accurate information presented, no warranty, expressed or implied, is offered. The participants should use their clinical judgment, knowledge, experience, and diagnostic decision-making skill before applying any information, whether provided here or by others, for any professional use.

Commercial Support Acknowledgment

This activity is supported by an educational grant from sanofi-aventis.

Enter the Activity